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ChemotherapyAbstract Gestational trophoblastic disease (GTD) is a term used for a group of pregnancy-related
tumors. Gestational trophoblastic neoplasia (GTN), is recognized as the most curable gynecologic
malignancy. However, many cases are resistant to ﬁrst line chemotherapy. We present cases of inva-
sive mole. They were diagnosed as a vesicular mole on ultrasonography and underwent suction and
evacuation but vaginal bleeding recurred with plateau and rising B-hcg with intramyometrial vas-
cular lesion. Hysterectomy was done that indicated invasive mole. Patients were cured of their
symptoms. Surgical therapy (hysterectomy) with chemotherapy has shown to achieve remission
in these cases especially with resistance to chemotherapy and in perimenopause.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gestational trophoblastic disease is divided into molar and
non-molar tumors. Non-molar tumor are grouped as
Gestational trophoblastic neoplasia (GTN) (1). GTN are clas-
siﬁed histologically into three distinct subgroups invasive
mole, choriocarcinoma, and placental site trophoblastic tumor
(PSST) (2).
Invasive mole follows approximately 10–15% of complete
hydatiform mole. The prognosis for most cases of GTN is
characterized by the presence of wide spread of metastasis.
Invasive mole (IM) is common manifestation of GTNcharacterized by the presence of whole chorionic villi that
accompany excessive trophoblastic overgrowth and invasion.
These tissues penetrate deep into the myometrium sometimes
involving the peritoneum or vaginal vault. Such moles are
locally invasive but generally lack the pronounced tendency
to develop widespread metastases typical of choriocarcinoma.
IM originates exclusively from complete or partial mole (3,4).
2. Case series
2.1. Case Report 1
A 30 yr old married female, G3P2+1, with history of vaginal
delivery, was admitted to our hospital with regular heavy men-
strual bleeding since 12 months after evacuation of vesicular
mole. She had done ultrasonography and was diagnosed as
vesicular mole, she underwent suction and evacuation proce-
dure since 12 months ago. She had irregular vaginal bleeding
with persistent elevated and plateau B-hcg, so she started
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with B-hcg plateau at level of 20 IU/L for over 2 months with
regular menses. The patient came complaining of positive
urine and serum pregnancy test with no pregnancy for months
and regular menses.
On examination her vitals were stable. On per abdominal
examination uterus was just palpable and was corresponding
to a gestational age of 12 weeks size. On per speculum exami-
nation minimal bleeding was present. On bimanual examina-
tion uterus was bulky 12 weeks’ gestation age, no adnexal
mass palpable. All investigations were done which were nor-
mal and chest X-ray was normal. Ultrasound done well
deﬁned mass about 2 cm with multiple small cystic spaces
within the myometrium which was suggestive of invasive mole
(Fig. 1). Serum b-hCG done which was 20 mIU/ml. Oncologist
opinion was taken and patient was advised to do hysterectomy
because of resistant chemotherapy and non-compliant patient
after her request and consent. So, subtotal abdominal hysterec-
tomy with the preservation of both ovaries was done because
of young age of patient.
Cut section of uterus revealed multiple grape like vesicles
invading the myometrium (Fig. 2). Histopathological examina-
tion report of uterus came which was suggestive of Invasive
mole.
2.2. Case Report 2
A 45 year old lady, gravida 4, para 3 + 1, presented to our
department with irregular vaginal bleeding since 2 months
and elevated beta-human chorionic gonadotropin (B-HCG)
level after evacuation of vesicular mole with persistent elevated
B-hcg. The B-HCG was persistently elevated (5312 IU/ml).
Following this, B-HCG still continued to rise, reaching up to
7204 IU/ml. Her physical examination was unremarkable. A
transvaginal ultrasound scan was done that showed a hetero-
geneous mass about 4 cm in the myometrium, fundal region
of the uterus, away from the endometrium (Fig. 3), Color
Doppler showed prominent blood ﬂow signals within the
lesion suggestive of neovascularization and Pulsed Doppler
showed low vascular impedance arterial blood ﬂow. Both
ovaries were unremarkable. Based on the clinical history ofFig. 1 Ultrasound showing intramyometrial mass about 2 cm.molar pregnancy in the past, with persistently elevated
B-HCG levels, a sonographic diagnosis of an invasive mole
of the uterus was established. Chest X-ray was done which
did not reveal any abnormality. Oncologist opinion was taken
and patient was advised to do hysterectomy because of old age,
completed family size and non-compliant patient after her
request and consent. So, total abdominal hysterectomy with
preservation of both ovaries was done. Cut section of uterus
revealed multiple grape like vesicles invading the myometrium
(Fig. 4). Histopathological examination report of uterus came
which was suggestive of Invasive mole. Patient was
discharged with follow up. Medical therapy – Inj.
Methotrexate 1 mg/kg/day im alternate day with inj. Folinic
acid 0.1 mg/kg in four doses two cycles.
3. Discussion
GTN arises when the normal regulatory mechanism control-
ling the proliferation and invasiveness of trophoblastic tissue
are lost. These are rare and constitute less than 1% of all gyne-
cologic malignancy. They are characterized by a distinct tumor
marker b-hCG and have varying tendencies toward local inva-
sion and distant metastasis (5). Vascular invasion and metasta-
sis rarely occur in Invasive mole (6). Demonstration of
myometrial vascular mass without the evidence of fetal mate-
rial on USG in the context of an elevated b-hCG is highly sug-
gestive of GTN (IM) (7,8).
An invasive hydatiform mole is a form of GTN that occurs
due to abnormal proliferation of placental trophoblast.
It most commonly occurs after the evacuation of GTD. It is
characterized by the presence of edematous chorionic villi with
trophoblastic proliferation that invades into the myometrium
of the uterus or to adjacent structures such as the vagina,
vulva, broad ligament, and can also invade into the uterine
vessels (9). Invasive mole is unlike choriocarcinoma, the latter
is without the presence of chorionic villi. It is important to dis-
tinguish between invasive mole and choriocarcinoma, as the
former has a more favorable outcome.
The clinical presentation of an invasive mole includes vagi-
nal bleeding, an enlarged uterus and high urinary or serum
bHCG level, typically after the evacuation of a molar preg-
nancy. The interval from an antecedent molar pregnancy is
usually less than six months. Choriocarcinoma can occur after
a hydatiform mole or even after a normal pregnancy, with an
interval of more than six months, sometimes lasting for nearly
ten years. BHCG levels are much higher in choriocarcinoma
than in invasive mole (10).
Approximately 8% of patients with complete moles will
develop a malignant tumor after evacuation (11). Therefore
serial values of bHCG should be obtained after evacuation,
which if persistently elevated, should raise the suspicion of
GTN. The Cancer Committee of the International
Federation of Gynaecologists and Obstetricians (FIGO) has
established the following guidelines for the diagnosis of post
molar gestational trophoblastic neoplasia (8): four values or
more of bHCG plateaued over at least three weeks, an increase
in bHCG of 10% or greater for three or more values over at
least 2 weeks, the histological diagnosis of choriocarcinoma,
and persistence of bHCG six months after molar evacuation.
Ultrasound has become the standard protocol in aiding in
diagnosis of suspected GTN (12). B-mode ultrasound is useful
Fig. 2 Hysterectomy specimen showing intramyometrial mass with vesicles.
Fig. 3 Ultrasound with intramyometrial mass nearly 4 cm.
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Sonographically, an invasive hydatidiform mole, a placental
site trophoblastic tumor, and choriocarcinoma typically
exhibit a heterogenous, hyperechoic, solid mass with cystic
vascular spaces, located within the myometrium (13,14).
Color Doppler imaging aids in the assessment of angiogenesisFig. 4 Hysterectomy specimen showing hemorrhagand neovascularization characteristic in these tumors, seen as
prominent blood ﬂow signals in various directions suggestive
of arterial and venous ﬂow (15). Doppler velocimetric ﬁndings
in patients with invasive moles, placental site trophoblastic
tumors and choriocarcinoma are similar in that they all may
exhibit low-impedance arterial ﬂow and high velocity (10).
Bilateral enlarged ovaries due to theca lutein cysts may also
be seen (10).
The differential diagnosis of highly vascular, intramural
lesions of the myometrium seen by ultrasound includes arteri-
ovenous malformation, gestational trophoblastic neoplasia,
and interstitial pregnancy (8,16). It is possible to distinguish
between these entities, using a combination of both biochemi-
cal ﬁndings and ultrasound appearances. Demonstration of a
vascular mass within the myometrium without evidence of
fetal material, on ultrasonography, in the context of an ele-
vated bHCG is highly suggestive of GTN (8,17).
The pathological diagnosis of an invasive mole is rarely
made, because most cases are conservatively treated, without
the need for hysterectomy. Invasive mole is rarely metastatic,
if it does occurs, it is usually to the lungs. Metastases are much
more common in choriocarcinoma, common sites being the
lower genital tract, brain, liver, lung, kidney, and the gastroin-
testinal tract (18). The absence of metastases helps to rule toic mass in the uterus with vesicles on cutsection.
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oncology has made recommendations for the metastatic work
up of GTN, which includes a chest X-ray, liver CT when indi-
cated or a whole body CT scan in patients with lung metas-
tases, and a brain MRI (or CT) when there is a suspicion of
cerebral metastases.
Management of an invasive mole includes treatment with
chemotherapy as well as continued monitoring of bHCG.
Patients with GTN should be followed with weekly quantita-
tive bHCG levels until normal for three consecutive weeks,
then monthly for 12 months (19). Ultrasound and Color
Doppler have also been shown to be an effective tool in pre-
dicting the resolution or persistence of GTN post treatment
(20). Dilatation and curettage are not recommended due to
the risk of uterine perforation (9). With methotrexate, com-
plete remission is achieved in most non-metastatic and low risk
cases (21,22). Even in the presence of disseminated disease,
most of the cases are amenable to treatment with almost
100% survival. Hysterectomy is common in old age, resistance
to chemotherapy, poor compliance and completed family size.
4. Conclusion
Although the development of effective chemotherapy has
resulted in improved survival of the patients with GTD, hys-
terectomy remains an important adjunct in the treatment of
the selected subset of patients (6). Surgical therapy (hysterec-
tomy) performed with chemotherapy has shown to achieve
remission.
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